Selected data models

You must log in to select data models for download or further analysis.

11 Search results.
Relevance Rating New first Old first

Prostate Cancer Toxicity - E1805 - Adverse Event Prostated Cancer E1805

- 9/20/21 - 1 form, 6 itemgroups, 25 items, 1 language
Itemgroups: Header, ON TREATMENT, Adverse Event, Adverse event blood, bone marrow lab, Adverse event infection, Other Adverse Events
E1805 Adverse Event Form (CTCAE v3.0) Prostate Cancer Toxicity - E1805 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0F33944C-5CE4-6FA2-E044-0003BA3F9857

Serious adverse events GSK study Prostatic neoplasms NCT00883909

- 11/26/17 - 1 form, 14 itemgroups, 58 items, 1 language
Itemgroups: administrative data, Serious adverse event, Serious adverse event, SAE, Demography data, Recurrence of SAE, Causes of SAE, Relevant Medical Conditions, risk factors, concomitant medication, Drug Details, Assessments, Remarks, information Investigator
Study ID: 103094 Clinical Study ID: ARI103094 Study Title: ARI103094-Follow-Up Study for REDUCE Study Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00883909 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: dutasteride Trade Name: Zytefor,Zyfetor,Duagen,Avolve,Avodart,Avidart Study Indication: Neoplasms, Prostate

CRFs Cabazitaxel Prostate Cancer DRKS00006520 NCT01308580 Adverse Event - CRFs Cabazitaxel Prostate Cancer NCT01308580 Adverse Event

- 5/26/17 - 1 form, 4 itemgroups, 39 items, 1 language
Itemgroups: Adverse Event, Adverse Event - Ongoing without Change, Adverse Event - Ongoing with Change, Safety Complementary Form
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen Other drug name: Jevtana® Study Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT01308580 Sponsor: Sanofi

Radium-223 Dichloride (Alpharadin) DRKS00006460 NCT01618370 in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases (Adverse Events) - Radium 223 Dichloride (Alpharadin) - Adverse Events

- 3/20/17 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Adverse Events (Y/N), Adverse Events
This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC (Hormone refractory prostate cancer / Castrate resistant prostate cancer) patients diagnosed with bone metastasis and to collect additional short and long term safety data on the product. NCT01618370

NCT00288080 RTOG-0521 AE: Adverse Event Evaluation Form

- 7/8/15 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: RTOG clinical trial administrative data, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS
NCT00288080 RTOG-0521 AE: Adverse Event Evaluation Form Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F6AEEB67-8813-18D7-E034-0003BA3F9857

NCT00331773 RTOG-0415 AE: Adverse Event Evaluation Form

- 7/8/15 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: RTOG clinical trial administrative data, REPORT ALL CONTINUING OR NEW ADVERSE EVENTS
NCT00331773 RTOG-0415 AE: Adverse Event Evaluation Form Radiation Therapy in Treating Patients With Stage II Prostate Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=062815BB-E53D-47BE-E044-0003BA3F9857

E3805 Adverse Event Form - (CTCAE v3) NCT00309985

- 7/8/15 - 1 form, 11 itemgroups, 34 items, 1 language
Itemgroups: Header, Patient demographics, Data amendment, ON TREATMENT, OFF TREATMENT, Adverse Event Current Assessment, BLOOD/BONE MARROW - LABS, NON-HEMATOLOGIC, II. INFECTIONS, Other Adverse Events, Comments
E3805 Adverse Event Form - (CTCAE v3) NCT00309985 Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F9FCD590-0471-30E2-E034-0003BA3F9857

CALGB: 90202 ADVERSE EVENT FORM NCT00079001

- 7/8/15 - 1 form, 5 itemgroups, 19 items, 1 language
Itemgroups: Header, Patient demographics, AER/ADR filed?, EXPECTED ADVERSE EVENTS, CCRR MODULE
CALGB: 90202 ADVERSE EVENT FORM NCT00079001 Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B4606682-4CF2-0526-E034-0003BA12F5E7

Toxicity - Prostate Cancer - Adverse Event Form - 2283646v3.0 - Prostate Cancer - Adverse Event Form

- 1/9/15 - 1 form, 3 itemgroups, 17 items, 1 language
Itemgroups: CRF Header, Prostate: Adverse Events, Comments
Prostate Cancer - Adverse Event Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=DC4FB6C8-2D4F-5BF6-E034-0003BA12F5E7

Metastatic Cancer NCT00134056 Toxicity - SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT SUMMARY FORM: Step 2 Post-Chemo Form - 2464820v1.0 - SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT SUMMARY FORM: Step 2 Post-Chemo Form

- 1/9/15 - 1 form, 3 itemgroups, 20 items, 1 language
Itemgroups: Header, ADVERSE EVENTS, Comments
SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT SUMMARY FORM: Step 2 Post-Chemo Form Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0F9D4F4F-BA23-2F60-E044-0003BA3F9857

Metastatic Cancer NCT00134056 Toxicity - SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT FORM: Step 1 Randomization - 2305232v3.0 - SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT FORM: Step 1 Randomization

- 1/9/15 - 1 form, 3 itemgroups, 20 items, 1 language
Itemgroups: Header, ADVERSE EVENTS, Comments
SOUTHWEST ONCOLOGY GROUP S0421 ADVERSE EVENT FORM: Step 1 Randomization Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F15B0C64-8BEB-3314-E034-0003BA3F9857

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial